Kidney Week

Abstract: PO0588

Qatar National Program for Screening and Management of Vascular Calcification in Hemodialysis

Session Information

• Vascular Disease, Nephrolithiasis, and Mineral Metabolism: Clinical
  November 04, 2021 | Location: On-Demand, Virtual Only
  Abstract Time: 10:00 AM - 12:00 PM

Category: Bone and Mineral Metabolism

• 402 Bone and Mineral Metabolism: Clinical

Authors

• Fouda, Tarek Ahmed, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Tarek Ahmed Fouda, MD

• Hamad, Abdullah Ibrahim, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Abdullah Ibrahim Hamad,

• Mohamed, Mohamed Yahya Abdelhai, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Mohamed Yahya Abdelhai Mohamed,

• Alomari, Anees Jamil, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Anees Jamil Alomari,

• Alakhras, Alaa Ibrahim Omar, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Alaa Ibrahim Omar Alakhras,

• Amood, Abeer Ahmad, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Abeer Ahmad Amood,

• Abraham, Thresiamma, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Thresiamma Abraham,

• Farooqi, Farrukh Ali, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Farrukh Ali Farooqi,

• Aly, Sahar, Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Sahar Aly,

• Al-Ali, Fadwa M., Hamad Medical Corporation, Doha, AD DAWHAH, Qatar

Fadwa M. Al-Ali,

Background

Vascular calcification (VC) is an independent and important risk factor for cardiovascular events in (HD) patients.Trials aiming to reduce the progression of VC did not show a great success. We are presenting data from our national program for screening and management of VC in hemodialysis patients in State of Qatar.

Methods

All ambulatory HD patients in Qatar where included. Data were collected in 2020 from the Qatar national electronic medical record and it included all imaging studies (X-ray, echocardiogram, US, CT ). VC then were classified into mild, moderate or severe. Patients with any VC were started on a newly created protocol to decrease calcium load (shift to non-calcium phosphate Binder, reduce active vitamin D, and liberalize calcimemitic dosing).Figure1 shows new pathway of screening and management of VC in HDpatients.

Results

Total patients were 650 During the study period. 559 were screened for VC (86%).423 (75%) had VC.We were able to classify 286 patients (67%) of them based on severity of VC on radiological findings to mild 201(70%),moderate 59(21%) or severe 26(9%).Following interventions, percentage of patients with calcium level of normal range (2.1-2.55mmol/l) increased by 5% from 83% in March 2020 to 88% in December 2020 (p value=0.004).Phosphorus level was maintained in the range 0.81-1.8mmol/l by 82% and PTH level in the range 150-500pg/ml by 72%. calcium based phosphate binder tables used weekly decreased by30%.

Conclusion

we created a screening and management protocol for VC in HD patients. Our protocol was successfully implemented and the initial outcomes was very promising.A follow up imaging to identify progression of VC should be considered in further studies.